Top

Published in:

Open Access 01-06-2013 | NON-THEMATIC REVIEW

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

Authors: François-Clément Bidard, Tanja Fehm, Michail Ignatiadis, Jeffrey B. Smerage, Catherine Alix-Panabières, Wolfgang Janni, Carlo Messina, Costanza Paoletti, Volkmar Müller, Daniel F. Hayes, Martine Piccart, Jean-Yves Pierga

Published in: Cancer and Metastasis Reviews | Issue 1-2/2013

Abstract

In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.

Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine, 351(8), 781–791.PubMedCrossRef

Nole, F., Munzone, E., Zorzino, L., Minchella, I., Salvatici, M., Botteri, E., et al. (2008). Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Annals of Oncology, 19(5), 891–897.PubMedCrossRef

Nakamura, S., Yagata, H., Ohno, S., Yamaguchi, H., Iwata, H., Tsunoda, N., et al. (2010). Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer, 17(3), 199–204. doi:10.1007/s12282-009-0139-3.PubMedCrossRef

Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2009). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. Journal of Clinical Oncology, 28(1), 92–98.PubMedCrossRef

Liu, M.C., Mego, M., Nakamura, S., Nole, F., Pierga, J., Toi, M., et al. (2011). Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). Journal of Clinical Oncology, 29, suppl; abstr 10592.

Stathopoulou, A., Vlachonikolis, I., Mavroudis, D., Perraki, M., Kouroussis, C., Apostolaki, S., et al. (2002). Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Journal of Clinical Oncology, 20(16), 3404–3412.PubMedCrossRef

Bidard, F. C., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., et al. (2012). Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.Breast Cancer Research, 14(1), R29.PubMed

Bidard, F. C., Mathiot, C., Degeorges, A., Etienne-Grimaldi, M. C., Delva, R., Pivot, X., et al. (2010). Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Annals of Oncology, 21(9), 1765–1771.PubMedCrossRef

Giordano, A., Giuliano, M., De Laurentiis, M., Eleuteri, A., Iorio, F., Tagliaferri, R., et al. (2011). Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment. doi:10.1007/s10549-011-1645-5.

10.

Pierga, J. Y., Bidard, F. C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., et al. (2008). Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical Cancer Research, 14(21), 7004–7010.PubMedCrossRef

11.

Bidard, F. C., Mathiot, C., Delaloge, S., Brain, E., Giachetti, S., de Cremoux, P., et al. (2010). Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Annals of Oncology, 21(4), 729–733.PubMedCrossRef

12.

Rack, B., Schindlbeck, C., Andergassen, U., Lorenz, R., Zwingers, T., Schneeweiss, A., et al. (2010). Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. Cancer Research, 70, S6–5.CrossRef

13.

Riethdorf, S., Muller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., et al. (2010). Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research, 16(9), 2634–2645.PubMedCrossRef

14.

Rack, B., Juckstock, J., Gunthner-Biller, M., Andergassen, U., Neugebauer, J., Hepp, P., et al. (2011). Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics. doi:10.1007/s00404-011-1954-2.

15.

Paoletti, C., Connelly, M., Chianese, D., Brown, M., Muñiz, M., Rae, J. M., et al. (2011). Development of circulating tumor cell-endocrine therapy index in metastatic breast cancer patients. Cancer Research, 25 (Proceedings of the San Antonio Breast Cancer Symposium).

16.

Paoletti, C., Connelly, M.C., Chianese, D., Brown, M., Muñiz, M., Rae, J. M., et al. (2011). Multi-parameter molecular characterization of circulating tumor cells (CTC): development of a CTC-Endocrine Therapy Index (CTC-ETI). American Association for Cancer Research.

17.

Etienne-Grimaldi, M. C., Formento, P., Degeorges, A., Pierga, J. Y., Delva, R., Pivot, X., et al. (2011). Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. British Journal of Clinical Pharmacology, 71(6), 921–928. doi:10.1111/j.1365-2125.2010.03896.x.PubMedCrossRef

18.

Paik, S., Kim, C., & Wolmark, N. (2008). HER2 status and benefit from adjuvant trastuzumab in breast cancer. The New England Journal of Medicine, 358(13), 1409–1411.PubMedCrossRef

19.

Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Davidson, N. E., Geyer, C. E., Jr., et al. (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 29(25), 3366–3373.PubMedCrossRef

20.

Georgoulias, V., Bozionelou, V., Agelaki, S., Perraki, M., Apostolaki, S., Kallergi, G., et al. (2012). Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. Annals of Oncology, 23(7), 1744–1750.PubMedCrossRef

21.

Fehm, T., Muller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., et al. (2010). HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment, 124(2), 403–412. doi:10.1007/s10549-010-1163-x.PubMedCrossRef

22.

Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., et al. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proceedings of the National Academy of Sciences of the United States of America, 101(25), 9393–9398.PubMedCrossRef

23.

Fehm, T., Becker, S., Duerr-Stoerzer, S., Sotlar, K., Mueller, V., Wallwiener, D., et al. (2007). Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Research, 9(5), R74.PubMedCrossRef

24.

Spector, N. L., Xia, W., Burris, H., 3rd, Hurwitz, H., Dees, E. C., Dowlati, A., et al. (2005). Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. Journal of Clinical Oncology, 23(11), 2502–2512.PubMedCrossRef

25.

Edge, S.B., Byrd, D.R., Compton, C.C., et al. (2010). Breast. In: Edge, S.B., Byrd, D.R., Compton, C.C., et al. (Eds) AJCC cancer staging manual. (Vol. 7th ed., pp. 347–376). New York: Springer.

26.

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247.PubMedCrossRef

Title: Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
Authors: François-Clément Bidard
Tanja Fehm
Michail Ignatiadis
Jeffrey B. Smerage
Catherine Alix-Panabières
Wolfgang Janni
Carlo Messina
Costanza Paoletti
Volkmar Müller
Daniel F. Hayes
Martine Piccart
Jean-Yves Pierga
Publication date: 01-06-2013
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1-2/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9398-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2013

Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

Introduction

Stromal cells in tumor microenvironment and breast cancer

Animal models of leukemia: any closer to the real thing?

The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis

Mouse models of lung squamous cell carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer